🔥 STARBOARD at #ESMO26: enco + bini + pembro vs placebo + pembro, 1L BRAF V600 melanoma (n=220)
🖋️ Dirk Schadendorf
➡️ ORR 70% vs 33% | mPFS 33.0 vs 3.4 mo, HR 0.33 | OS HR 0.71 (90% CI 0.48-1.05)
☣️ G3-4 TEAEs 70% vs 39% | enco/bini discontinuation 43%
My two issues:
⚠️ Was pembro mono the right control? Fit BRAF-mutant pts get ipi-nivo
⚠️ Too few events for OS at 31 mo FU, though the trend favours the triplet
@myESMO @_SEOM @OncoAlert @LARVOL
623 views · 10 likes · 3 reposts · 0 replies
STARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgSource: Yago Garitaonaindía · x.com